Analyst Ratings For Pulmonx
Portfolio Pulse from Benzinga Insights
Analyst ratings for Pulmonx (NASDAQ:LUNG) have varied over the last quarter, with a recent shift towards a more positive outlook as evidenced by an increase in the average 12-month price target to $16.00 from $14.75. This change reflects adjustments in ratings and price targets by analysts from Wells Fargo, Stifel, and Piper Sandler, responding to Pulmonx's market dynamics and performance. Despite the positive revenue growth of 9.11% for the last 3 months, Pulmonx faces challenges with a net margin of -72.04%, ROE of -11.38%, and ROA of -7.66%, indicating potential difficulties in profitability and asset utilization.
February 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulmonx has seen a positive shift in analyst sentiment, with an increased average price target to $16.00, indicating a bullish outlook. However, the company's financial challenges, such as low net margin and ROE, may temper short-term stock performance.
The increase in the average price target by analysts suggests a more optimistic view of Pulmonx's future stock performance. However, the company's underlying financial issues, such as a significant net margin deficit and below-average ROE and ROA, could hinder its ability to capitalize on this positive sentiment in the short term. The mixed financial indicators suggest a cautious optimism among investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100